Targeting immune checkpoints in non small cell lung cancer

Andrea Bianco; Umberto Malapelle; Danilo Rocco; Fabio Perrotta; Gennaro Mazzarella

doi:10.1016/j.coph.2018.02.006

Targeting immune checkpoints in non small cell lung cancer

Curr Opin Pharmacol. 2018 Jun:40:46-50. doi: 10.1016/j.coph.2018.02.006. Epub 2018 Mar 9.

Authors

Andrea Bianco¹, Umberto Malapelle², Danilo Rocco³, Fabio Perrotta⁴, Gennaro Mazzarella³

Affiliations

¹ Department of Cardio-Thoracic and Respiratory Sciences - University of Campania "L Vanvitelli", Naples, Italy. Electronic address: andrea.bianco@unicampania.it.
² Department of Public Health - University of Naples "Federico II", Naples, Italy.
³ Department of Cardio-Thoracic and Respiratory Sciences - University of Campania "L Vanvitelli", Naples, Italy.
⁴ Lungs for Living Research Centre - University College of London, London, UK.

PMID: 29525401
DOI: 10.1016/j.coph.2018.02.006

Abstract

Cancers have the ability to disrupt immune response by interfering with adaptive immunity. Blocking checkpoint pathways has become a target for pharmacological research in lung cancer with particular focus on peptides PD-1 and CTLA-4. A number of immune check-point inhibitors (ICIs) targeting both PD-1 and CTLA-4 pathways are under investigation within clinical trials, of which Nivolumab, Pembrolizumab and Atezolizumab have already been approved for lung cancer treatment by both FDA and EMA. Employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC) ICIs have exhibited advantages in terms of overall survival and response rate with some responses being durable. Evaluating combinations of different inhibitors, dosing and sequencing within a multimodal therapy approach, together with better management of toxicity represents a new challenge for future research of therapy targeting immune check-points.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
CTLA-4 Antigen / antagonists & inhibitors*
CTLA-4 Antigen / immunology
CTLA-4 Antigen / metabolism
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / metabolism
Carcinoma, Non-Small-Cell Lung / pathology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / metabolism
Lung Neoplasms / pathology
Molecular Targeted Therapy
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Programmed Cell Death 1 Receptor / metabolism
Signal Transduction / drug effects

Substances

Antineoplastic Agents, Immunological
CTLA-4 Antigen
CTLA4 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor